Pneumonia in Medical Technology
Navigation Links
Pneumonia in Medical Technology
... upper respiratory tract infection, myalgia and pneumonia (each 12%), muscle cramps (11%), and dehydration ... studies. The most commonly reported SAEs included pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), ... 10%), rash (19% vs 7%), back pain (17% vs 18%), pneumonia (16% vs 11%), dizziness (16% vs 11%), dyspnea ...
... in patients with cSSSIs and hospital-acquired pneumonia (HAP), ventilator-acquired pneumonia (VAP) or healthcare-associated pneumonia (HCAP). Arpida is also pursuing the development ...
... Most Important Factors Driving Nosocomial pneumonia Prescribing in Hospitals Are Infectious Disease ... see how they would compete within the nosocomial pneumonia drug market. The new report entitled Hospital Anti-Infectives Insight Series: Nosocomial pneumonia found that the ceftobiprole analogue profile is ...
... of a serious complication: Ventilator Acquired pneumonia (VAP). In a peer review 2007 report in Physical ... by Stephen P. Burns MD, the incidence of SCI pneumonia for initial admitted patients was reported to be ... high as 50 percent. The associated mortality from pneumonia was reported as 28% in the first year. ...
... of adult patients with community-acquired pneumonia (CAP). Before granting approval, the FDA ... Community-Acquired Pneumonia CAP is defined as pneumonia acquired outside a hospital or long-term care ... decreased ability to function normally. Although pneumonia is not a reportable illness, it appears that up ...
... the treatment of patients with community-acquired pneumonia (CAP). The FDA now will complete its review ... System in Akron, Ohio. About Community-Acquired pneumonia CAP is defined as pneumonia not acquired in a hospital or long-term care ...
... clinically cure 81% of patients with nosocomial pneumonia (NP), and 68% of patients with ... product in Japan in September 2005. Nosocomial pneumonia is acquired in either a hospital or ... 48 hours after admission. Ventilator-associated pneumonia is a form of nosocomial pneumonia which occurs in ...
... outpatient treatment of adults with mild-to-moderate community acquired pneumonia (CAP) (11 positive, 3 negative, 1 abstaining). However, the committee ... approved for this or any other indication. About Community Acquired pneumonia (CAP) CAP is the sixth most common cause of death in the United ...
... events (SAEs) during the studies. The most commonly reported SAEs included pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, ... edema peripheral (20% vs 10%), rash (19% vs 7%), back pain (17% vs 18%), pneumonia (16% vs 11%), dizziness (16% vs 11%), dyspnea (15% vs 13%), headache (14% ...
... zoster, nasopharyngitis, upper respiratory tract infection, myalgia and pneumonia (each 12%), muscle cramps (11%), and dehydration and anxiety (each 10%). ... events (SAEs) during the studies. The most commonly reported SAEs included pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, ...
... events (SAEs) during the studies. The most commonly reported SAEs included pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, ... arrest, congestive heart failure, respiratory failure, renal failure, pneumonia and sepsis. For more information about VELCADE clinical trials, patients ...
... events (SAEs) during the studies. The most commonly reported SAEs included pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, ... arrest, congestive heart failure, respiratory failure, renal failure, pneumonia and sepsis. For more information about VELCADE clinical trials, patients ...
... events (SAEs) during the studies. The most commonly reported SAEs included pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, ... arrest, congestive heart failure, respiratory failure, renal failure, pneumonia and sepsis. For more information about VELCADE clinical trials, patients ...
... benefit and resources required relative to potential risk to pneumocystis pneumonia (PCP) patients does not support further development for this target ... Inc.'s business, including the future prospects for Pneumocystis pneumonia (PCP). Except for historical information, the matters discussed in this ...
... key susceptible and resistant pathogens involved in community acquired pneumonia (CAP), while others reviewed safety data in certain special clinical ... bacterial resistance observed in the treatment of community acquired pneumonia (CAP). Cethromycin has been tested in approximately 5,000 human subjects ...
... key susceptible and resistant pathogens involved in community acquired pneumonia (CAP), while others reviewed safety data in certain special clinical ... bacterial resistance observed in the treatment of community acquired pneumonia (CAP). Cethromycin has been tested in approximately 5,000 human subjects ...
... been granted Orphan Drug Designation for treatment of pneumocystis pneumonia (PCP) and malaria. In addition to trials for African sleeping sickness, ... clinical programs that include new oral treatments for Pneumocystis pneumonia (PCP), malaria, and trypanosomiasis (HAT or African Sleeping Sickness), ...
... leakage. ALI is caused by any stimulus of local or systemic inflammation and commonly occurs after acute insults to the body, such as trauma, severe pneumonia and sepsis. ALI is a key factor on the pathway to mortality following severe influenza infection. About IC14 IC14 is a clinical stage ...
... of temperature, oxygen saturation, respiratory rate, systolic blood pressure and heart rate. This type of endpoint has previously been used in pneumonia studies, but not in influenza. Secondary objectives of the study included evaluation of viral shedding, mortality, clinical relapse and time to ...
... bacterial, viral, fungal, and protozoan infections can occur in patients receiving Campath. Administer prophylaxis against Pneumocystis jiroveci pneumonia (PCP) and herpes virus infections. Campath is indicated as a single agent for the treatment of B-cell chronic lymphocytic ...
... reported: arthralgia, rash, hypersensitivity, pulmonary hemorrhage, hemorrhage and epistaxis. Two patients in the placebo group died, one of fungal pneumonia and the other of pulmonary hemorrhage. One case of disease progression from MDS to acute myeloid leukemia was observed in the Nplate 500ug treated ...
... when administered to a pregnant woman. Nursing should be discontinued in women taking TEMODAR. Prophylaxis against Pneumocystis carinii pneumonia is required for all patients receiving concomitant TEMODAR and radiotherapy for the 42-day regimen. There may be a higher occurrence of PCP when ...
... vs 10%), asthenia (21% vs 18%), cough (21% vs 13%), insomnia (20% vs 13%), edema peripheral (20% vs 10%), rash (19% vs 7%), back pain (17% vs 18%), pneumonia (16% vs 11%), dizziness (16% vs 11%), dyspnea (15% vs 13%), headache (14% vs 10%), pain in extremity (14% vs 9%), abdominal pain (14% vs 7%), ...
... bacterial, viral, fungal, and protozoan infections can occur in patients receiving Campath. Administer prophylaxis against Pneumocystis jiroveci pneumonia (PCP) and herpes virus infections. Campath is indicated as a single agent for the treatment of B-cell chronic lymphocytic ...
... all caused by the bacterium Streptococcus pneumoniae, that include invasive infections such as bacteremia/sepsis and meningitis, as well as pneumonia and otitis media. Most recently, the pneumococcal serotype 19A, which is included in the candidate vaccine, has been increasing in prevalence in ...
... in patients with cSSSIs and hospital-acquired pneumonia (HAP), ventilator-acquired pneumonia (VAP) or healthcare-associated pneumonia (HCAP). Arpida is also pursuing the development ...
... Most Important Factors Driving Nosocomial pneumonia Prescribing in Hospitals Are Infectious Disease ... see how they would compete within the nosocomial pneumonia drug market. The new report entitled Hospital Anti-Infectives Insight Series: Nosocomial pneumonia found that the ceftobiprole analogue profile is ...
... of a serious complication: Ventilator Acquired pneumonia (VAP). In a peer review 2007 report in Physical ... by Stephen P. Burns MD, the incidence of SCI pneumonia for initial admitted patients was reported to be ... high as 50 percent. The associated mortality from pneumonia was reported as 28% in the first year. ...
... of adult patients with community-acquired pneumonia (CAP). Before granting approval, the FDA ... Community-Acquired Pneumonia CAP is defined as pneumonia acquired outside a hospital or long-term care ... decreased ability to function normally. Although pneumonia is not a reportable illness, it appears that up ...
Amikacin Inhale Shows Promising Results in Phase II Study
... II data for the adjunctive treatment of pneumonia in intubated and ... for the adjunctive treatment of Gram-negative pneumonia in intubated and mechanically-ventilated ... pneumonia. 'Gram-negative pneumonia' refers to pneumonia caused by a laboratory-defined group of ...Arpida Provides Further Comments on the Pivotal Phase III Trials
... meeting discussing Community-Acquired pneumonia (CAP) in which the panel unanimously confirmed ... the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP). In January 2008, the US FDA granted ...... the treatment of patients with community-acquired pneumonia (CAP). The FDA now will complete its review ... System in Akron, Ohio. About Community-Acquired pneumonia CAP is defined as pneumonia not acquired in a hospital or long-term care ...
Chinese SFDA Grants Immtech Fast Track Status
... drug candidate for the treatment of Pneumocystis pneumonia (PCP). Pafuramidine is among the first drugs to ... lungs and can cause potentially life-threatening pneumonia in patients with HIV and other ... that include new oral treatments for Pneumocystis pneumonia (PCP), malaria, and trypanosomiasis (African ...... clinically cure 81% of patients with nosocomial pneumonia (NP), and 68% of patients with ... product in Japan in September 2005. Nosocomial pneumonia is acquired in either a hospital or ... 48 hours after admission. Ventilator-associated pneumonia is a form of nosocomial pneumonia which occurs in ...
... outpatient treatment of adults with mild-to-moderate community acquired pneumonia (CAP) (11 positive, 3 negative, 1 abstaining). However, the committee ... approved for this or any other indication. About Community Acquired pneumonia (CAP) CAP is the sixth most common cause of death in the United ...
... events (SAEs) during the studies. The most commonly reported SAEs included pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, ... edema peripheral (20% vs 10%), rash (19% vs 7%), back pain (17% vs 18%), pneumonia (16% vs 11%), dizziness (16% vs 11%), dyspnea (15% vs 13%), headache (14% ...
Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
... safety and efficacy of delafloxacin in the treatment of community acquired pneumonia (CAP). In this study, the compound was shown to be effective at doses as ... against methicillin-resistant S. aureus, multidrug-resistant Streptococus pneumonia and S. pyogenes. Additionally, Rib-X is developing delafloxacin, ...Arpida Announces Review of Iclaprim NDA by FDA Advisory Committee in November 2008
... intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP). In May 2008, Arpida announced the enrolment of the first ...Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
... intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP). In May 2008, Arpida announced the enrolment of the first ...... zoster, nasopharyngitis, upper respiratory tract infection, myalgia and pneumonia (each 12%), muscle cramps (11%), and dehydration and anxiety (each 10%). ... events (SAEs) during the studies. The most commonly reported SAEs included pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, ...
... events (SAEs) during the studies. The most commonly reported SAEs included pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, ... arrest, congestive heart failure, respiratory failure, renal failure, pneumonia and sepsis. For more information about VELCADE clinical trials, patients ...
... events (SAEs) during the studies. The most commonly reported SAEs included pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, ... arrest, congestive heart failure, respiratory failure, renal failure, pneumonia and sepsis. For more information about VELCADE clinical trials, patients ...
Arpida Enrols First Patients in "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
... intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP). In January 2008, the US FDA granted authorisation to progress ...... events (SAEs) during the studies. The most commonly reported SAEs included pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, ... arrest, congestive heart failure, respiratory failure, renal failure, pneumonia and sepsis. For more information about VELCADE clinical trials, patients ...
More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL
... sought approval of TYGACIL for the treatment of community-acquired pneumonia (CAP). Wyeth's action is based on its understanding of the Committee for ... The safety and efficacy of TYGACIL in patients with hospital-acquired pneumonia have not been established -- In clinical trials, the most common ...Arpida Invited to Present Data on Iclaprim at Scientific Conference
... intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP). In January 2008, the US FDA granted authorisation to progress ...... benefit and resources required relative to potential risk to pneumocystis pneumonia (PCP) patients does not support further development for this target ... Inc.'s business, including the future prospects for Pneumocystis pneumonia (PCP). Except for historical information, the matters discussed in this ...
Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma
... events (SAEs) during the studies. The most commonly reported SAEs included pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, ... arrest, congestive heart failure, respiratory failure, renal failure, pneumonia and sepsis. This integrated analysis does not include the Phase III, ...Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin
... Application (NDA) submission for cethromycin to treat community acquired pneumonia (CAP). The U.S. Food and Drug Administration (FDA) requires thorough QT ... (international), passcode 10008184. About Community Acquired pneumonia (CAP) CAP is the sixth most common cause of death in the United States. ...Replidyne Provides Strategic Update
... faropenem in acute bacterial sinusitis (ABS) and community-acquired pneumonia (CAP) until a partner is identified. -- Business development. Replidyne ... infections including acute bacterial sinusitis (ABS), community-acquired pneumonia (CAP) and acute exacerbation of chronic bronchitis (AECB). Faropenem is a ...Immtech Reports Fiscal Second Quarter 2008 Results
... to conduct a Phase III trial with pafuramidine, to treat pneumocystis pneumonia in HIV/AIDs patients. The Company will hold a conference call on Friday, ... clinical programs that include new oral treatments for pneumocystis pneumonia (PCP), malaria, and trypanosomiasis (African sleeping sickness or HAT), ...... key susceptible and resistant pathogens involved in community acquired pneumonia (CAP), while others reviewed safety data in certain special clinical ... bacterial resistance observed in the treatment of community acquired pneumonia (CAP). Cethromycin has been tested in approximately 5,000 human subjects ...
... key susceptible and resistant pathogens involved in community acquired pneumonia (CAP), while others reviewed safety data in certain special clinical ... bacterial resistance observed in the treatment of community acquired pneumonia (CAP). Cethromycin has been tested in approximately 5,000 human subjects ...
... been granted Orphan Drug Designation for treatment of pneumocystis pneumonia (PCP) and malaria. In addition to trials for African sleeping sickness, ... clinical programs that include new oral treatments for Pneumocystis pneumonia (PCP), malaria, and trypanosomiasis (HAT or African Sleeping Sickness), ...
... leakage. ALI is caused by any stimulus of local or systemic inflammation and commonly occurs after acute insults to the body, such as trauma, severe pneumonia and sepsis. ALI is a key factor on the pathway to mortality following severe influenza infection. About IC14 IC14 is a clinical stage ...
Complications and Costs for Obesity Surgery Declining
... was driven by a reduction in the post-surgical infection rate, which plummeted 58 percent. Abdominal hernias, staple leakage, respiratory failure and pneumonia fell by between 50 percent and 29 percent. Rates for other complications, such as ulcers, dumping (involuntary vomiting or defecation), ...... of temperature, oxygen saturation, respiratory rate, systolic blood pressure and heart rate. This type of endpoint has previously been used in pneumonia studies, but not in influenza. Secondary objectives of the study included evaluation of viral shedding, mortality, clinical relapse and time to ...
... bacterial, viral, fungal, and protozoan infections can occur in patients receiving Campath. Administer prophylaxis against Pneumocystis jiroveci pneumonia (PCP) and herpes virus infections. Campath is indicated as a single agent for the treatment of B-cell chronic lymphocytic ...
... reported: arthralgia, rash, hypersensitivity, pulmonary hemorrhage, hemorrhage and epistaxis. Two patients in the placebo group died, one of fungal pneumonia and the other of pulmonary hemorrhage. One case of disease progression from MDS to acute myeloid leukemia was observed in the Nplate 500ug treated ...
... when administered to a pregnant woman. Nursing should be discontinued in women taking TEMODAR. Prophylaxis against Pneumocystis carinii pneumonia is required for all patients receiving concomitant TEMODAR and radiotherapy for the 42-day regimen. There may be a higher occurrence of PCP when ...
... vs 10%), asthenia (21% vs 18%), cough (21% vs 13%), insomnia (20% vs 13%), edema peripheral (20% vs 10%), rash (19% vs 7%), back pain (17% vs 18%), pneumonia (16% vs 11%), dizziness (16% vs 11%), dyspnea (15% vs 13%), headache (14% vs 10%), pain in extremity (14% vs 9%), abdominal pain (14% vs 7%), ...
... bacterial, viral, fungal, and protozoan infections can occur in patients receiving Campath. Administer prophylaxis against Pneumocystis jiroveci pneumonia (PCP) and herpes virus infections. Campath is indicated as a single agent for the treatment of B-cell chronic lymphocytic ...
... all caused by the bacterium Streptococcus pneumoniae, that include invasive infections such as bacteremia/sepsis and meningitis, as well as pneumonia and otitis media. Most recently, the pneumococcal serotype 19A, which is included in the candidate vaccine, has been increasing in prevalence in ...
New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria
... and pyelonephritis (2); complicated intra-abdominal infections (cIAI) (2); nosocomial pneumonia (NP), including early-onset ventilator-associated pneumonia (VAP) (1); and VAP, both early- and late-onset (1). The study results showed: -- Against ESBLE and CIPRE, doripenem was generally more potent in ...Other ContentsphimosisphlebotomyphlebitisphlegmphlegmexaminationexaminationexaminationexaminationexaminationexaminationexaminationexaminationphobiasphobiasactivityactivityactivityactivityactivityactivityactivityactivityactivityactivityOther TagsLampsLampsEDTAEDTAOther Tagshasten 2composite 2fall 2fall 3fall 4fall 5fall 6fall 7fall 8fall 9fall 10history 2history 3history 4history 5history 6history 7history 8history 9history 10join 2join 3clotting 2
(Date:11/25/2009)... the California Institute of Technology (Caltech) ...e behavior in the fruit fly, Drosophila melanogas... the relationship between the neurotransmitter dop... (ADHD), are described in the December issue of th...tains only about 20,000 neurons and has long been ...
(Date:11/25/2009)...ave easy lives. In addition to mammalian immune sy...mies called bacteriophages, viruses that kill half... bacteria and another class of microorganisms call...ts such as deep-sea volcanic vents) manage just fi...n defense system that helps protect them from many...
(Date:11/25/2009)...the Cell Death Research Laboratory in the Universi...ded the prestigious Johnson & Johnson Focused Fund...brain cell damage in Parkinson,s disease. The awar...port of innovation and excellence in science, was ...r this month at an event at the Hyatt Regency Hote...
Breaking Biology News(10 mins):Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 2Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 3Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 4Researchers discover biological basis of 'bacterial immune system' 2Researchers discover biological basis of 'bacterial immune system' 3Johnson & Johnson award goes to research of the cause of brain cell damage in Parkinson's 2Women 26apos 3Bs Health Expert Dr Susan Lark Featured on Searchbloodsugar com 50863 1Women 26apos 3Bs Health Expert Dr Susan Lark Featured on Searchbloodsugar com 50863 2Women 26apos 3Bs Health Expert Dr Susan Lark Featured on Searchbloodsugar com 50863 3Frost 26 Sullivan Identifies Innovative and Cost Effective Technology as Key Competitive Factor in European Medical Device Market 50860 1Frost 26 Sullivan Identifies Innovative and Cost Effective Technology as Key Competitive Factor in European Medical Device Market 50860 2Frost 26 Sullivan Identifies Innovative and Cost Effective Technology as Key Competitive Factor in European Medical Device Market 50860 3Video 3A FDA Approves Hologics Adiana 28R 29 Permanent Contraception System 50858 1Video 3A FDA Approves Hologics Adiana 28R 29 Permanent Contraception System 50858 2Video 3A FDA Approves Hologics Adiana 28R 29 Permanent Contraception System 50858 3Video 3A FDA Approves Hologics Adiana 28R 29 Permanent Contraception System 50858 4Video 3A FDA Approves Hologics Adiana 28R 29 Permanent Contraception System 50858 5(Date:11/26/2009)...fluseasonuponus,it,smoreimportantthanevertoemployg...illness. ,, "Weneedtobeproactivenotonlytokeepou...esick,"saidEileenFinerty,RN,MS,CIC(certifiedininfe...ndoccupationalhealthatHospitalforSpecialSurgery(HS...neofthelowestinfectionratesofanyhospitalinthecount...
(Date:11/26/2009)... living with diabetes will nearly double, increasi...34. Over the same period, spending on diabetes wil...billion, even with no increase in the prevalence o...Chicago report in the December issue of Diabetes ...ed by Medicare will rise from 8.2 million to 14.6 ...
(Date:11/26/2009)... strains or worse , , THURSDAY, Nov. 26 ...h stuffing your turkey full to bursting, but you m...ase as you pack for holiday trips. , More than ...l emergency rooms, doctors, offices, clinics and o...es, such as muscle strains, pulls and tears, accor...
(Date:11/26/2009)...the North Pole, Textsanta.net lets parents sign up... North Pole, AK (PRWEB) -- In a...he North Pole Santa Claus has added SMS text messa...rmed of his Christmas progress at the North Pole.,...e identified a large and growing percentage of Ame...
(Date:11/26/2009)...tal (RTDental), a leading dental group practice in...sion of its services to include LUMINEERS by a cer... Durham, NC (PRWEB) -- Res...Dr. Doug Macmillan, an experienced LUMINEERS Den...aining seminar. RTDental’s ability to fulfi...
Breaking Medicine News(10 mins):Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3Health News:Pack Right for the Holidays to Avoid the ER 2Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2[1] Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use[0] Diabetes cases to double and costs to triple by 2034[2] Pack Right for the Holidays to Avoid the ER[1] Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes[0] Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |